Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%. By fortuneindia.com
